CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 611 enrolled
Drug / intervention
TD-4208 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02512510
NCT02512510Phase 3Completed
CompareCT.gov

A Phase 3, 12-week, Randomized, Double-blind Placebo-controlled Parallel Group Study of Nebulized TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease

Mylan Inc.·interventional·Posted Jul 31, 2015·Updated Feb 24, 2022

In Brief

A Phase 3 clinical trial evaluating TD-4208 and Placebo for Chronic Obstructive Pulmonary Disease (COPD). Completed, enrolled 611 participants across 1 site.

Detailed Summary

The purpose of this study is to measure the effectiveness and safety of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to placebo, a treatment without activity.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Obstructive Pulmonary Disease (COPD)
CountriesUnited States
CollaboratorsTheravance Biopharma

Timeline

Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedJul 31, 2015
Enrollment StartSep 1, 2015
Primary CompletionAug 1, 2016
Study CompletionSep 1, 2016
TodayJul 2, 2026
Enrollment to primary: 11 monthsPosted 10.9 years ago

Interventions

TD-4208drug

Placebodrug